Animalcare Group acquired by CHARTERHOUSE

The acquisition of Animalcare Group by Charterhouse Capital Partners represents a major consolidation opportunity within the global animal healthcare sector, officially concluding the target's tenure as a publicly traded entity on the London Stock Exchange's AIM market. Implemented by way of a scheme of arrangement under Part 26 of the Companies Act 2006, the recommended cash offer allows the European private equity firm to take full control of the veterinary pharmaceutical platform. The transaction is structured to offer immediate liquidity to existing shareholders through a definitive cash exit, representing a significant premium to the volume-weighted average price over the preceding three and six-month periods. Alternatively, the financial architecture of the buyout integrates a reinvestment mechanism, enabling eligible shareholders, including key management figures like CEO Jennifer Winter and institutional backer Harwood Capital, to roll over a portion of their proceeds into the newly formed private holding structure (Topco Units via an Aggregator). This dual-offer framework secures robust stakeholder support, culminating in irrevocable undertakings to vote in favor of the scheme. The strategic thesis driving the take-private operation is centered on providing the target with the financial flexibility required to accelerate its intensive clinical discovery cycles away from public market scrutiny. The private equity sponsor intends to deploy significant capital expenditure and operating expenses to fund early-stage biologic development and execute off-market, transformational mergers that might prove overly dilutive for a listed company. Stifel acted as the independent financial advisor to the target's board of directors, ensuring the commercial viability of the terms amid a volatile macroeconomic environment. Following the successful delisting, the unified entity will focus strictly on scaling its international presence while benefiting from the robust strategic alignment between the management team and the new institutional shareholder.